TxCell strengthens its board of directors by appointing Dr. David Solomon to board and as Chair of sub-committee

TxCell strengthens its board of directors by appointing Dr. David Solomon to board and as Chair of sub-committee

Valbonne, France, April 16, 2015 – TxCell SA, a biotechnology company developing innovative, cost-effective, personalized T cell immunotherapies using antigen specific regulatory T-cells (Ag-Tregs) for severe chronic inflammatory and autoimmune diseases, today announces that it has appointed Dr. David Solomon as an additional independent member of the board and Chair of the Remuneration and Nominations sub-committee of the board.

Dr. David Solomon has extensive experience as a CEO in a number of listed biotech companies as well as other companies involved in healthcare investing and pharmacology research. Dr. Solomon is currently the President and CEO of Bionor, a NASDAQ OMX Oslo listed therapeutic vaccine company based in Oslo, Norway, with other offices in Copenhagen, Denmark, and New York, US.

"TxCell is delighted to further strengthen the board with the appointment of Dr. David Solomon. David will add to TxCell a considerable depth of experience across the biotech and healthcare investing sectors gained in both Europe and the US," said François Meyer, Executive Chairman, TxCell. "TxCell's development of Ovasave(R), its lead personalized T-cell immunotherapy in refractory Crohn's disease and Col-Treg, its second product candidate from the ASTrIA product platform for the treatment of autoimmune uveitis, benefits from a board with an enviable set of specialist skills, experience and expertise."

Prior to joining Bionor, Dr. Solomon was CEO of Zealand Pharma A/S (NASDAQ: ZEAL) from 2008 to 2015. From 2003 to 2006 he headed healthcare investing at Carrot Capital Healthcare Ventures in New York, US. Dr. Solomon has held several leadership positions at a number of biotechnology, pharmaceutical and medical device companies, including Remedy Pharmaceuticals, Critical Diagnostics and Vital Sensors. In addition, he is currently on the boards of Onxeo in Paris (Euronext and NASDAQ OMX) and Promosome, in La Jolla, CA, US. 

Dr. Solomon studied medicine and immunology at Cornell Medical College and the Sloan Kettering Cancer Center in New York where he received his doctorate in 1991. Dr. Solomon has served as a faculty member at Columbia University's College of Physicians and Surgeons.

"TxCell's innovative personalized T-cell immunotherapies are at the forefront of one of the most exciting new areas in medicine. TxCell's approach has the potential to create life-changing therapies for patients suffering from a range of severe chronic and refractory autoimmune inflammatory diseases," said David Solomon. "I am delighted to join the Board of TxCell and to be able to bring my experience to support the development of TxCell and its potentially life-changing therapies."

About TxCell
TxCell develops innovative, cost-effective, personalized T cell immunotherapies for the treatment of severe chronic inflammatory diseases with high medical need. TxCell has created ASTrIA, a unique and proprietary product platform based on the properties of autologous antigen-specific regulatory T lymphocytes (Ag-Tregs). The company has initiated a phase IIb study of its lead product candidate, Ovasave(R) in refractory Crohn's disease patients. This follows a phase I/IIa study in the same patient population reporting positive clinical efficacy and good tolerability. TxCell has a strategic partnership for the development of Ovasave with the Swiss company Trizell Holding SA and Ferring International Center remains the intended final commercializing party. Both companies are affiliates of the Dr Frederik Paulsen Foundation. TxCell's second product candidate, Col-Treg is for the treatment of autoimmune uveitis, a rare disease of the eye. A placebo-controlled, dose-ranging proof of principle clinical study is planned to start in the first half of 2015. Listed on Euronext-Paris, TxCell, a spin-off of Inserm (France's National Institute for Health and Medical Research) is located in the Sophia Antipolis technology park, Nice, France. The company has 65 employees based at its headquarters and at its manufacturing site in Besançon. For more information, please visit www.txcell.com

Suggested Articles

Preclinical-stage biotech Abpro Therapeutics wants to trial its two lead candidates for HER2-positive cancers and diabetic macular edema in 2019.

After a rough patch in 2017, the stars seem to be realigning for French CAR-T expert Cellectis, which just closed a $164 million U.S. public offering.

Investment firm Frazier Healthcare Partners has closed its 11th fund—worth $780 million—that will help established companies accelerate their growth.